<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04604691</url>
  </required_header>
  <id_info>
    <org_study_id>20197007</org_study_id>
    <nct_id>NCT04604691</nct_id>
  </id_info>
  <brief_title>Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)</brief_title>
  <official_title>Blinatumomab for Minimal Residual Disease Before Hematopoietic Stem Cell Transplantation With Pediatric B-cell Precursor Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, multi-center phase I study using blinatumomab for pediatric&#xD;
      B-cell acute lymphoblastic leukemia patients with positive of minimal residual disease. 1&#xD;
      Cycle of blinatumomab treatment followed by hematopoietic stem cell transplantation.&#xD;
      Blinatumomab has approved to treat adults and children with B-cell precursor ALL who are in&#xD;
      remission but still have MRD. However, data on the effects and safety of blinatumomab in&#xD;
      children with B-precursor ALL with MRD positive are insufficient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation including cytokine release syndrome</measure>
    <time_frame>At the latest possible timepoint prior to the initiation of transplant conditioning or after 30 days of Blinatumomab treatment</time_frame>
    <description>The incidence of treatment-emergent and treatment-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete MRD response status after 1 cycle of blinatumomab</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Relapse-Free Survival (RFS)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pediatric ALL, B Cell</condition>
  <condition>Minimal Residual Disease</condition>
  <arm_group>
    <arm_group_label>Blinatumomab Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab for Injection</intervention_name>
    <description>Blinatumomab will be administered as a continuous intravenous (CIV) infusion at a constant flow rate over four weeks followed by a two-week infusion free interval.</description>
    <arm_group_label>Blinatumomab Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Immunophenotypic evidence of Cluster of Differentiation 19 (CD19) positive B precursor&#xD;
             ALL&#xD;
&#xD;
          -  Age &lt;18 years at the time of informed consent/assent&#xD;
&#xD;
          -  B cell precursor ALL in first or later hematologic complete remission (CR) defined as&#xD;
             less than 5% blasts in bone marrow after at least three intense chemotherapy blocks&#xD;
&#xD;
          -  Persistent or recurrent MRD ≥10^-4 in an assay with a minimum sensitivity of 10^-5&#xD;
             before hematopoietic stem cell transplantation&#xD;
&#xD;
          -  Bone marrow function as defined below: Absolute neutrophil count ≥1,000/μL, Platelets&#xD;
             ≥50,000/μL (transfusion permitted), Hemoglobin level ≥9 g/dL (transfusion permitted)&#xD;
&#xD;
          -  Renal and hepatic function as defined below: Aspartate aminotransferase (AST), Alanine&#xD;
             aminotransferase (ALT), and alkaline phosphatase (AP) &lt; 2 x upper limit of normal&#xD;
             (ULN), Total bilirubin &lt;1.5 x ULN, Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Negative HIV test, negative hepatitis B (HBsAg) and hepatitis C virus (anti-HCV) test&#xD;
&#xD;
          -  Negative pregnancy test in women of childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of circulating blasts or current extramedullary involvement by ALL&#xD;
&#xD;
          -  History of relevant central nervous system (CNS) pathology or current relevant CNS&#xD;
             pathology (e.g. seizure, epilepsy, paresis, aphasia, stroke, severe brain injuries,&#xD;
             dementia, cerebellar disease, organic brain syndrome, psychosis) with the except of&#xD;
             CNS leukemia that is well controlled with intrathecal therapy&#xD;
&#xD;
          -  Current infiltration of cerebrospinal fluid by ALL&#xD;
&#xD;
          -  History of or active relevant autoimmune disease&#xD;
&#xD;
          -  Systemic cancer chemotherapy within 2 weeks prior to study treatment (except for&#xD;
             intrathecal prophylaxis)&#xD;
&#xD;
          -  Radiotherapy within 4 weeks prior to study treatment&#xD;
&#xD;
          -  Autologous hematopoietic stem cell transplantation (HSCT) within six weeks prior to&#xD;
             study treatment&#xD;
&#xD;
          -  Therapy with monoclonal antibodies (rituximab, alemtuzumab) within 4 weeks prior to&#xD;
             study treatment&#xD;
&#xD;
          -  Treatment with any investigational product within 4 weeks prior to study treatment&#xD;
&#xD;
          -  Known hypersensitivity to immunoglobulin or to any other component of the study drug&#xD;
             formulation&#xD;
&#xD;
          -  Active malignancy other than ALL with the exception of basal cell or squamous cell&#xD;
             carcinoma of the skin, or carcinoma &quot;in situ&quot; of the cervix&#xD;
&#xD;
          -  Active infection, any other concurrent disease or medical condition that are deemed to&#xD;
             interfere with the conduct of the study as judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Jin Kang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyoung Jin Kang, MD</last_name>
    <phone>+82-2-2072-3452</phone>
    <email>kanghj@snu.ac.kr</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blinatumomab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

